CAS: 329319-20-2

Sanggenol L, a compound from the root bark of Morus alba, inhibits cell growth and promotes apoptotic cell death in melanoma skin cancer cells through activation of the cysteinyl asparaginase cascade and apoptosis-inducing factors. Sanggenol L has anticancer activity and antiproliferative effects and is used in the study of prostate cancer.

Sanggenol L is a phytochemical compound, which is a type of flavonoid. It is derived from the root bark of the Morus alba L., commonly known as the white mulberry tree. This compound is characterized by its intricate phenolic structure, contributing to its diverse biological activities. The mode of action of Sanggenol L is primarily through its interaction with cellular oxidative pathways, where it exerts antioxidant effects by scavenging free radicals. Additionally, it has been observed to modulate various signaling pathways involved in inflammation and may inhibit key enzymes related to these processes. This multifaceted interaction with cellular components underscores its potential as a therapeutic agent. The uses and applications of Sanggenol L are extensive, with research indicating potential roles in combating oxidative stress-related conditions, such as neurodegenerative diseases, cardiovascular disorders, and inflammation-related pathologies. Its bioactivity suggests that it may serve as a lead compound for the development of novel therapeutic agents targeting oxidative and inflammatory processes in various disease models. Further research into its precise mechanisms and therapeutic potential continues to be a subject of scientific inquiry.